Zepbound can lead to some serious side effects, although they are rare
However, these medications, classified as GLP-1 receptor agonists (for Semaglutide) and dual GLP-1/GIP receptor agonists (for Tirzepatide), are now being explored for a variety of other potential health benefits beyond their established uses including: improving cardiovascular health, exerting neuroprotective effects, exhibiting anti-inflammatory properties, ad potentially benefitting conditions such as polycystic ovary syndrome (PCOS) and chronic kidney disease
however, these symptoms are very similar between the different presentations of disease
A study published in the New England Journal of Medicine found that individuals taking semaglutide for 68 weeks lost an average of 14.9% of their body weight
The MRI study also indicated the development of a contiguous, expansile lesion at the T5 vertebral body associated with right ventral epidural extension (Fig
The fat loss from around the middle of the body was not merely due to overall fat loss, because the ratio of abdominal fat to total fat was also significantly reduced